Takeda Gets Second Chance With U.S. FDA Complete Response On Actos Combo Drug
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Takeda Pharmaceutical stated this week that it has received a complete response letter from U.S. FDA; the American drug regulator stated in the letter that the NDA review for a fixed-dose alogliptin and Actos (pioglitazone) combo drug will depend on additional data from a cardiovascular safety study FDA requested for the company's alogliptin monotherapy NDA